Indivior PLC - Richmond, Virginia-based maker of medicines to treat substance use disorders - Completes share buyback programme begun in July. Indivior buys back 9.4 million shares at average £8.25, worth £77.7 million, about $100.0 million, in total. The buyback was run by Morgan Stanley & Co International PLC. Last week, Indivior promoted David Wheadon to chair, starting immediately. Wheadon joined the Indivior board in June last year. Wheadon is a medical doctor who worked for GlaxoSmithKline, now GSK PLC, and Eli Lilly & Co. Until 2019, he was senior vice president of global regulatory affairs, patient safety & quality assurance at AstraZeneca PLC.
Current stock price: 930.00 pence each, down 1.3% on Tuesday morning in London
12-month change: down 32%
Copyright 2025 Alliance News Ltd. All Rights Reserved.
